Gender specificity in the interpretation of treatment results for patients with colorectal cancer in the Republic of Tatarstan

Аннотация

Objectives – to identify the gender-specific features of modeling the prognosis of treatment outcomes for patients with colorectal cancer (CRC).

Materials and methods. The study included 654 patients with colorectal cancer (CRC) who were treated from 2013 to 2015, of which 434 were men, 220 were women. The average age of the patients was 64.1±10.2 years. All patients underwent genetic analysis for the presence of a mutation in the KRAS gene from the primary tumor. 

Results. The gender approach to assessing the long-term results of treatment of patients with CRC showed that in men with colorectal cancer, the most favorable treatment results were observed in patients with tumors in stage T 1-2 N0 M0, regardless of the differentiation of the tumor and its mutational status. In men, poorly differentiated tumors with any T, with the presence of regional metastases and a mutation of the KRAS gene, even in the absence of distant metastases, should be considered prognostically unfavorable: not a single patient lived for 5 years. In women, based on the decision tree analysis, the most favorable treatment results were observed in patients with tumors in the stage T 1-2-3 N0 M0 under the age of 70 years (five-year survival rate of 90%), with tumors T 1-2 N0 M0 – over the age of 70 years (five-year survival of 81.8%), regardless of the differentiation of the tumor and its mutational status. Tumors of any differentiation of the T3-4 N0 stage with the presence of distant metastases (5% of patients lived for 5 years) and poorly differentiated T4N0M0 tumors (five-year survival of 8%) are prognostically unfavorable for women. 

Conclusion. The study of gender and age-related features of the development and course of CRC is relevant for oncologists to select effective diagnostic, therapeutic and rehabilitation measures.

Conflict of Interest: nothing to disclose.

Список литературы

1. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. (In Russ.). doi: 10.33 22/caac.21492

2. Kaprin AD. State of cancer care for the population of Russia in 2018. Russian center for information technologies and epidemiological research in oncology. (In Russ.).

3. Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015:21(17):5167–75. doi: 10.3748/wjg.v21. i17.5167

4. Zharkova OS, Sharopin KA, Seidova AS, et al. Building decision support systems in medicine based on a decision tree. Modern science-intensive technologies. 2016;6–1:33–37. (In Russ.). doi: 10.17513/snt.37918

5. Smagulova KK, Kaidarova DR, Chichua NA, Ishkinin EI. Study of the frequency and spectrum of KRAS gene mutations in patients with colorectal cancer (CRR) depending on the prevalence of the process. Electronic journal "Modern problems of science and education". 2019;3. (In Russ.). doi: 10.17513/spno.28909

6. Vodolazhsky DI, Antonets AV, Dvadnenko KV, et al. Association of KRAS gene mutations with clinical and pathological features of colorectal cancer in patients of the South of Russia. Medical journal of international education. 2014;1:65–68. (In Russ.). doi: 10.1200/jco.2015.33.15_suppl.e18534

7. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9:1193–1197. doi: 10.1002/gcc.10125

8. Selcukbiricik F, Erdamar S, Ozkurt CU, et al. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON. 2013;18:116–123. doi: 10.1007/s13277-013-0763-6

9. Eli M, Mollayup A, Muattar J, Liu C, et al. K-ras genetic mutation and influencing factor analysis for Han and Uygur nationality colorectal cancer patients. Int J Clin Exp Med. 2015;8(6):10168–77. doi: 10.1097/md.0000000000010234

10. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86. doi: 10.1002/ijc.29210

11. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res. 2013;19:5842–5848. doi: 10.1158/1078-0432.ccr-13-0325

Для цитирования

Gataullin BI, Khasanov RSh, Savelev AA, Gataullin IG. Gender specificity in the interpretation of treatment results for patients with colorectal cancer in the Republic of TatarstanScience& Innovations in Medicine. 2020;5(2):124-129 .doi: 10.35693/2500-1388-2020-5-2-124-129

Request

Send an online application form to the publication

Send